To determine how an MDM2 inhibitor might affect the response to SX-682 in melanoma, we performed experiments combining the MDM2 inhibitor, idasanutlin (50mg/kg), with SX-682 in B16F10 melanoma and we observed that idasanutlin reduced the effect of SX-682 on tumor growth inhibition (Figure 7A) and reversed the inhibitory effects of SX-682 on the Ly6G+CD11b+ granulocytic MDSCs (Figure 7B) and also increased the CD206+ M2 macrophages in the blood (Figure 7C). Here, ITGAM is linked to neoplasm.